^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AiRuiLi (adebrelimab)
i
Other names: SHR1316, SHR-1316, SHR 1316, HTI-1088, HTI-1316, HTI1088, HTI 1088, HTI 1316, HTI1316
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hengrui Pharma
Drug class:
PD-L1 inhibitor
Related drugs:
6d
SYSKY-2023-1262-02: Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=32, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Sep 2026 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
Trial completion date • Trial primary completion date
|
AiTan (rivoceranib) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
7d
Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial (clinicaltrials.gov)
P2, N=84, Not yet recruiting, Sun Yat-sen University
New P2 trial • pMMR
|
5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • AiRuiLi (adebrelimab)
7d
Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
P2, N=58, Not yet recruiting, Harbin Medical University
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
12d
Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma (clinicaltrials.gov)
P1/2, N=40, Not yet recruiting, Sun Yat-sen University
New P1/2 trial
|
zeprumetostat (SHR-2554) • AiRuiLi (adebrelimab)
12d
SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
P2, N=93, Active, not recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting
Enrollment closed
|
Avastin (bevacizumab) • cisplatin • gemcitabine • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
12d
OBU-HCC-II-001: Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma (clinicaltrials.gov)
P2, N=40, Suspended, Tianjin Medical University Cancer Institute and Hospital | Trial completion date: Aug 2027 --> Aug 2028 | Recruiting --> Suspended | Trial primary completion date: May 2025 --> May 2027
Trial completion date • Trial suspension • Trial primary completion date
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • AiRuiLi (adebrelimab)
13d
FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov)
P2, N=716, Recruiting, Fudan University | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • FOXC1 (Forkhead Box C1)
|
Herceptin (trastuzumab) • carboplatin • Focus V (anlotinib) • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • Andewei (benmelstobart) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Idafang (ivonescimab) • bulumtatug fuvedotin (9MW2821) • AiRuiLi (adebrelimab) • IBI-354 • SHR-4602 • TQB2102 • TQB2868 • anbenitamab repodatecan (JSKN003) • tizetatug rezetecan (SHR-A1921)
13d
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC (clinicaltrials.gov)
P2, N=90, Recruiting, Tang-Du Hospital | Not yet recruiting --> Recruiting
Enrollment open
|
cisplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
15d
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
P1/2, N=130, Recruiting, Fudan University | N=35 --> 130 | Trial completion date: Sep 2026 --> Mar 2028 | Trial primary completion date: Jun 2026 --> Jun 2027
Enrollment change • Trial completion date • Trial primary completion date
|
Avastin (bevacizumab) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • HRS-4642
19d
Neoadjuvant adebrelimab combined with triplet chemotherapy for locally advanced resectable adenocarcinoma of esophagogastric junction: a prospective, single-arm, phase II feasibility and safety study. (PubMed, J Gastrointest Oncol)
While perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) remains the global standard for locally advanced resectable AEG, its substantial hematologic toxicity and perioperative tolerability concerns may limit broader adoption in some Asian patients in real-world clinical practice. This study aimed to assess the perioperative feasibility and safety of neoadjuvant adebrelimab combined with chemotherapy (nab-paclitaxel, lobaplatin, and S-1) in patients with resectable, locally advanced AEG...Neoadjuvant adebrelimab combined with triplet chemotherapy demonstrated acceptable perioperative feasibility, manageable toxicity, and preliminary pathological antitumor activity in patients with locally advanced AEG. Given the exploratory single-arm design and short follow-up, the findings should be considered hypothesis-generating and require validation in larger multicenter randomized trials.
P2 data • Journal
|
PD-L1 (Programmed death ligand 1)
|
docetaxel • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur) • lobaplatin (D19466) • AiRuiLi (adebrelimab)
22d
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer (clinicaltrials.gov)
P1/2, N=55, Recruiting, West China Hospital
New P1/2 trial
|
5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • AiRuiLi (adebrelimab)
22d
ANCRE: Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=37, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
New P2 trial
|
carboplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
Share via
